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Abstract
Malignant rhabdoid tumors (MRTs) are poorly differentiated pediatric cancers that arise in various
anatomical locations and have a very poor outcome. The large majority of these malignancies are
caused by loss of function of the SNF5/INI1 component of the SWI/SNF chromatin remodeling
complex. However, the mechanism of tumor development associated with SNF5 loss remains
unclear. Multiple studies have demonstrated a role for SNF5 in the regulation of cyclin D1,
p16INK4A and pRbf activities suggesting it functions through the SWI/SNF complex to affect
transcription of genes involved in cell cycle control. Previous studies in genetically engineered
mouse models (GEMM) have shown that loss of SNF5 on a p53 null background significantly
accelerates tumor development. Here, we use established GEMM to further define the relationship
between the SNF5 and p53 tumor suppressor pathways. Combined haploinsufficiency of p53 and
Snf5 leads to decreased latency for MRTs arising in alternate anatomical locations but not for the
standard facial MRTs. We also observed acceleration in the appearance of T-cell lymphomas in
the p53+/-;Snf5+/- mice. Our studies suggest that loss of SNF5 activity does not bestow a selective
advantage on the p53 spectrum of tumors in the p53+/-;Snf5+/- mice. However, reduced p53
expression specifically accelerated the growth of a subset of MRTs in these mice.
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Although representing only a small percentage of pediatric neoplasms, malignant rhabdoid
tumors (MRTs) are particularly devastating, killing the majority of affected children before
their second birthday. These aggressive tumors, first described in the kidney, were originally
defined as “rhabdoid” due to the morphological resemblance of the tumor cells to
rhabdomyoblasts [1]. However, further characterization of these tumor cells including the
lack of expression of myogenic transcription factors established them as distinct from
rhabdomyoblasts [1-3]. Rhabdoid tumors are now recognized to occur in diverse locations
including the brain, spinal cord, liver, chest wall, and face [4-6]
MRTs have always presented a diagnostic challenge given the largely undifferentiated
although heterogeneous appearance, polyphenotypic immunoprofiles, and similarities to
other tumor types. The designation of MRT historically relied on the histological appearance
of large epithelioid cells with eccentric eosinophilic cytoplasm, vesicular nuclei, prominent
nucleoli, and whorled bundles of intermediate filaments. These characteristic rhabdoid cells,
described above, are frequently not the predominant cell in a malignant rhabdoid tumor,
even appearing rarely in some tumors. Therefore, false diagnoses were frequent. The
discovery of deletions and mutations at 22q11.2 involving SNF5/INI1 has since facilitated
diagnosis and treatment evaluation [7-11]. SNF5 function is now recognized as being lost in
almost 100% of MRTs [12]. The finding that genetic alterations in MRTs are usually limited
to SNF5 mutations and deletions, without chromosome- or genome-wide losses or
instability, strongly implicates the loss of SNF5 function as the primary cause of these
tumors [12-14].
Studies using genetically engineered mouse models (GEMM) have verified SNF5’s specific
role in tumor suppression. Snf5 nullizygotes are embryonic lethal, dying at peri-implantation
stage while loss of SNF5 activity at birth in conditional Snf5 mice cause death within 3
weeks due to hematopoietic failure [15-18]. A reversible conditional mutant that causes only
partial penetrance of SNF5 loss avoids the bone marrow failure and death experienced with
the fully penetrant conditional mutation [16]. However, it shows a fully penetrant
phenotype, developing CD8+ T cell lymphomas or MRTs by 11 weeks [16]. In comparison,
loss of either tumor suppressor genes p53 or p16INK4A leads to tumor development at
median ages of 20 weeks and 38 weeks, respectively [19,20]. Therefore, the aggressive
phenotype observed in the reversible conditional mice makes Snf5 the most rapidly lethal
cancer mutation observed in GEMM following inactivation of a single gene.
GEMM offer the opportunity to examine the interactions between different oncogenic and
tumor suppressive pathways in an in vivo system. For example, Guidi et al. demonstrated
that Snf5 loss may be epistatic to Rb loss [21]. However, a more recent study showed that
loss of the entire Rb family accelerated MRT development [22]. These data seem to fit with
the etiology of human disease where MRTs do not appear to lose Rb or p16INK4A function.
Gene expression array analyses have also shown that inactivation of SNF5 function in
normal mouse embryo fibroblasts alters the expression of genes regulated by the E2F
transcription factor family [23].
As mentioned above, SNF5 mutations/deletions seem to be the only genetic alterations that
appear in MRTs in humans. While most malignancies found in adults harbor inactivating
mutations of the p53 tumor suppressor gene, the mutation frequency in MRTs remains
uncharacterized [24,25]. Therefore, several groups examined the effects of p53 loss on the
development of MRT in different Snf5 GEMM. Isakoff et. al. reported that simultaneous
inactivation of p53 and SNF5 activity in GEM accelerated the development of CD8+/CD4-
mature T cell lymphomas in 100% of the mice [23]. They further showed an accumulation
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of p53 in SNF5 deficient cells in culture displaying growth defects followed by apoptosis. In
contrast, the SNF5 deficient cells on the p53-null background showed a reduced level of
apoptosis. Yaniv and colleagues further demonstrated that p53 nullizygosity accelerated
tumor formation in Snf5 heterozygous mice - with complete penetrance within 19 weeks
(from 30% penetrant at 60 weeks on wild type p53 background). Neither the tumor
spectrum, nor anatomical locations of the resultant MRTs and sarcomas were altered [26].
This implies a true cooperation, not simply additive effect, as all tumors were SNF5-
deficient tumors in the same locations found in Snf5+/- mice on a wild type p53 background,
but with a much reduced latency and 100% penetrance [26]. Both groups suggested that p53
loss blocked apoptosis associated with SNF5 inactivation in normal cells and accelerated the
appearance of the SNF5-deficient tumors [23,26].
While these studies indicate that combined p53 and SNF5 inactivation accelerates the
progression of MRT development in GEMM, both studies used p53 nullizygous mice.
Therefore, they did not address the potential effects that SNF5 inactivation might have on
tumor development in a p53 heterozygous state. To address this question, we characterized
tumor development in p53+/-, Snf5+/- and p53+/- ;Snf5+/- mice. Our results reveal that
cooperation between these two important tumor suppressor pathways leads to a reduced
latency period but not an apparent increase in tumor penetrance. However, with the possible
exception of T cell lymphomas, we do not observe a decrease in the latency period for the
spectrum of tumors associated with the p53+/- mice. Rather, we find more rapidly arising
MRTs in the p53+/- ;Snf5+/- mice developing in anatomical sites infrequently observed in the
Snf5+/- mice alone.
MATERIAL AND METHODS
Generation of p53+/-; Snf5+/- mice
The generation, screening and characterization of p53+/- [27] and Snf5+/- [22] mice were
described previously. Snf5+/-;p53+/- mice were derived by crossing p53+/- mice with Snf5+/-
mice. Mice with resulting genotypes, Snf5+/+;p53+/-, Snf5+/-;p53+/+, Snf5+/-;p53+/- and
Snf5+/+;p53+/+ were born with the expected Mendelian frequencies. p53+/- mice were
maintained on a BDF1 C57BL/6 background and Snf5+/- mice were maintained on a
C57BL/6 × 129/SV mixed background following procedures approved by the Institutional
Animal Care and Use Committees. To minimize potential genetic background effects, all
experimental mice used in this study were derived from the same 2 female parental Snf5+/-
mice. Mice were monitored twice a week for 24 months or until a tumor or evidence of a
tumor (paralysis, swelling, extreme lethargy, etc) was observed. Mice were sacrificed by
CO2 asphyxiation followed by cervical dislocation as approved by the Institutional Animal
Care and Use Committees.
Histology
Tumor samples and selected tissues were fixed in 10% buffered formalin and sent to the
UNC Histopathology Core Facility for paraffin embedding and staining with eosin and
hematoxylin. Because of the importance of establishing the identity of each tumor, the
histopathology was evaluated independently by 2 senior investigators with previous
experience in the area of GEMM for soft tissue sarcomas- Dr. C. Fletcher at Harvard
University and Dr. V. Godfrey at University of North Carolina [15,16,22]. Each pathologist
evaluated H&E and immunohistochemistry slides in a blinded fashion to further reduce bias.
There was initial agreement upon the diagnosis in approximately 90% of the tumors. Cases
in disagreement centered SNF5-deficient tumors with scant evidence of typical rhabdoid cell
morphology being classified as MRT or sarcoma-non otherwise specified or NOS.
Therefore, by agreement, we classified all SNF5-deficient tumors as MRT.
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Product Forward primer Reverse primer
wild type Snf5 allele CAGGAAAATGGATGCAACTAAGAT CACCATGCCCCCACCTCCCCTACA
mutant Snf5 allele GGCCAGCTCATTCCTCCCACTCAT CACCATGCCCCCACCTCCCCTACA
wild type p53 allele ACAGCGTGGTGGTACCTTAT TATACTCAGAGCCGCCCT
mutant p53 allele TCCTCGTCGTTTACGGTATC TATACTCAGAGCCGGGCCT
Genotyping Analyses
DNA was extracted from mouse toes, tumors or organs using the Qiagen DNAeasy Kit for
animal tissues. All PCR reactions were carried out as previously described using EasyStart
0.5mL PCR tubes (MolecularBioProducts #6022) [22,27]. The following additions were
made to the EasyStart tube: 1-3ul of DNA extracted from mouse toes, Taq DNA
polymerase, specific primers for the mutant or wild type alleles, and ddH2O.
Immunohistochemistry
For histology, sections were stained with hematoxylin and eosin as described [28]. Tumors
were fixed in 10% formalin for 16-20 hrs and five μ sections were cut after embedding
tissues in paraffin. For IHC analysis, a tissue microarray consisting of triplicate 5μm cores
of 31 tumors at different locations in the recipient block from p53+/-, Snf5+/- and
Snf5+/-;p53+/- mice was constructed by the Anatomic Pathology Translational Core
Laboratory using a Pathology Devices (Westminster, MD) semi-automated TMArrayer. We
also included normal mouse tissues including lung, kidney and lymph nodes as controls.
IHC was carried out using the Vectastain Elite ABC Kit from Vector Laboratories following
manufacturer’s directions, as previously described [22]. All sections were quenched in 3%
hydrogen peroxide in methanol for 10 min at room temperature, washed in PBS three times
and then blocked in 5% goat serum. Sections were incubated with the primary antibody at
4°C overnight. After washing in PBS three times, the sections were incubated with an anti-
rabbit antibody (1:333, Vector, Burlingame, CA) at room temperature for 30 min followed
by washing in TS-T buffer (50 mM Tris pH 7.6, 150 mM NaCl, and 0.1% Tween-20) three
times. Elite ABC reagent (Vector, Burlingame, CA) was then added to the sections at room
temperature for 30 min followed by two washes in TS-T buffer. Stains were developed in
DAB (diaminobenzidine tetrahydrochloride) (DAKO, Carpinteria, CA) at room temperature
for 2-10 minutes, rinsed in PBS, and counter-stained in Light Green Counterstain or
hematoxylin (Biomeda, Foster City, CA). Sections were rinsed in H2O and dehydrated
before being mounted in Permacent (Fisher Scientific, Pittsburgh, PA). Microscopy was
performed with a Zeiss Axioplan 2 Microscope. All antibodies used are included in the table
below.
Antibodies
ANTIBODY Brief Description Source
SNF5 Mouse monoclonal Transduction Labs, 612110
Vimentin Rabbit polyclonal Biomeda V2009
S100ß Rabbit polyclonal Dako Z0311
p53 (CM5) Rabbit polyclonal Novacastra Labs NCL-p53-CM5p
CD3 Rabbit polyclonal Cell Marque CMC363
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ANTIBODY Brief Description Source
B220 Mouse monoclonal BD Pharmingen 550286
RESULTS
SNF5 heterozygosity leads to increased penetrance and decreased latency of tumor
formation on p53+/- background
Previous studies have shown combined nullizygosity of SNF5 and p53 leads to increased
tumor formation, but this occurs at a rate no longer compatible with life, with 100% lethality
within 7 weeks [23]. We crossed Snf5+/- females with p53+/- males to yield the
Snf5+/-;p53+/- double heterozygous mice, as well as control genotypes: Snf5+/-;p53+/+,
Snf5+/+;p53+/+, and Snf5+/+,p53+/- (see Materials and Methods for background strain and
origin of mice). The overall survival of these genotypes can be seen in Figure 1 and Table 1.
In the p53 heterozygote mice, we observed the expected >50% penetrance and 14.5 month
median age (range- 11 to 17.5 months) similar to that observed in previous p53+/- mouse
studies [19,27]. Sixty percent of Snf5+/- mice developed tumors with a median age of 15
months (range- 9-20 months), somewhat higher than in the original reports [15,17,18]. The
mice heterozygous for both p53 and Snf5, however, had a median age of tumor formation of
only 9.5 months (range- 2 to 17.5 months), and a total penetrance of approximately 80%.
Thus, the Snf5+/-; p53+/- mice show both an increase in tumor penetrance and an overall
reduction in latency similar to previous reports using Snf5+/-;p53-/- mice [23,26].
Snf5+/-;p53+/- mice develop MRTs, Lymphomas, and Osteosarcomas
As shown by Donehower in 1992 and Harvey in 1993, approximately 50% of p53+/- mice
develop tumors by 18 months of age [19,29]. The spectrum of tumors includes primarily
lymphomas (~30%) and osteosarcomas (~60%) as well as soft-tissue sarcomas and
carcinomas. We also observed a similar spectrum of tumors in our mice with the appearance
of 5 lymphomas, 3 osteosarcomas, 1 sarcoma NOS and 1 adenocarcinoma (Table 1). The
Snf5+/- mice form primarily malignant rhabdoid tumors of the soft tissues of the head and
neck, as well as spinal cord tumors, a pattern that we have consistently found in our Snf5+/-
mice. There were 5 facial MRTs and one spinal cord MRT resulting in hind limb paralysis
(Table 1).
Approximately 80% of the Snf5+/-;p53+/- mice developed tumors by 17.5 months. Twenty-
one out of the 32 mice (66%) had tumors that were classified as MRT. The remaining mice
had tumors consistent with the p53+/- mouse spectrum including 5 lymphomas, 4 sarcomas
NOS, 2 osteosarcomas and 1 fibrosarcoma. Therefore, it appeared the combined Snf5+/- and
p53+/- genotypes did not alter the tumor spectrum of either parental genotype as no tumors
completely novel to either genotype were observed. However, a significant change in the
anatomical sites of MRTs occurred in the Snf5+/-;p53+/- mice. While the MRTs arose only in
the face and spinal cords of the Snf5+/- mice, MRTs appeared in sites in the Snf5+/-;p53+/-
mice infrequently or rarely found in the Snf5+/- mice including the limbs, back and
intestines.
Loss of SNF5 Expression Occurs in Tumors with Decreased Latency in Snf5+/-;p53+/- Mice
Previous studies from several groups using Snf5+/- mouse models have shown virtually
100% LOH in MRTs that arise in these mice [15,17,18]. Due to T-cell infiltration and the
high vascularity of these tumors, we could not obtain reliable results by PCR-based assays.
Therefore, we generated a tissue array containing 5 tumors from Snf5+/- mice, 6 tumors
from p53+/- mice and 18 tumors from Snf5+/-;p53+/- mice (Table 2). We also included
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normal lung, kidney and lymph node tissue as controls. We then stained and scored each
array for expression of SNF5 and p53 protein by IHC. We found that all normal tissues
expressed SNF5 protein at high levels (supplemental data).
We first examined the tumors that arose in the p53+/- mice including 3 lymphomas and 3
osteosarcomas. All tumors were positive for SNF5 expression consistent with their wild-
type genetic background (Table 2). In contrast, the MRTs that arose in the Snf5+/- mice
showed no SNF5 protein expression indicating that inactivation of the remaining wild-type
Snf5 allele had taken place (Table 2, Figure 2).
We next examined 18 representative tumors from the Snf5+/-;p53+/- mice including 10
MRTs, 3 sarcoma NOSs, 2 osteosarcomas and 3 lymphomas. As expected, all MRTs arising
on the face of the mice (5/5) did not express SNF5 protein similar to the MRTs from the
Snf5+/- mice (Table 2; Figure 2). Furthermore, the ages of onset for these facial tumors did
not differ significantly between these groups (Table 2- gray shaded areas). The
osteosarcomas retained SNF5 protein expression and also arose in a similar timeframe as the
osteosarcomas in the p53+/- mice (Table 2). However, the remaining tumors fell into 2
classes. Lymphomas and sarcoma NOSs appearing on the limbs that arose in a similar
timeframe as tumors in the p53+/- mice retained SNF5 expression (Table 2). In contrast,
those tumors that had lost SNF5 expression showed decreased latency (<9 months, Table 2-
stippled areas). Perhaps, tumor #93 proved most informative (Figure 2). Although this limb
sarcoma NOS appeared after 13 months, it contained both an area of SNF5 positive staining
and an apparently emerging area of SNF5-negative tumor growth. Interestingly, the H&E
shows a more “rhabdoid” appearance in the SNF5-negative section of the tumor suggesting
that loss of SNF5 was directing the tumor towards a rhabdoid identity.
We also stained the tissue arrays for p53 expression. Immunohistochemistry analyses for
p53 protein expression do not provide clear evidence for loss of expression in tumors
because normal tissues show variable levels of expression. Therefore, while we could not
determine the status of p53 expression in most of our tumor samples, some of our results
were suggestive. Both normal lung and lymph node showed low levels of p53-positive
staining cells (supplemental data). Interestingly, 3/5 facial MRTs from both Snf5+/- and
Snf5+/-;p53+/- mice showed the same low-level p53 staining. In contrast, all 6 tumors from
the p53+/- mice and 13/13 of the remaining tumors from the Snf5+/-;p53+/- mice showed no
p53 staining.
The Immunoprofile of Mouse Malignant Rhabdoid Tumors Recapitulates Their Human
Counterparts
One question about the validity of GEMM for human cancers is how accurately they
embody the features of their representative human malignancy. The haploinsufficient Snf5
mouse has been well characterized as producing MRTs with histologies similar to those
observed in humans. We also examined a limited number of immunohistochemical markers
to determine whether the MRTs in the Snf5+/- mice showed a similar pattern to their human
counterparts. We also looked at the immunoprofile in a representative set of MRTs from the
Snf5+/-;p53+/- mice to assess whether loss of p53 function affected the phenotype of these
tumors. Approximately 60% of the MRTs, from either genotype, were positive for S100ß
expression, a somewhat lower frequency than our previous report [22] (Table 3). We also
observed a low to high level of expression of vimentin, an intermediate filament found in
cells of mesenchymal origin, in all MRTs (Table 3). These results appear consistent with
those found in human MRTs [30-33]. Furthermore, the immunophenotype of MRTs that
arose in the Snf5+/-;p53+/- mice did not appear to differ from those found in the Snf5+/-
mice.
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T-cell Lymphomas Arise in Snf5+/-;p53+/- mice
We had also previously found that induction of SNF5 inactivation in Mx+;Snf5cond/- mice
led to the rapid induction of T-cell lymphomas, a process accelerated by the co-inactivation
of p53 expression [16,23]. Previous reports indicated that lymphomas arising in p53+/- mice
also appeared to arise primarily from T cells [19,27]. Therefore, we determined the origin of
the lymphomas that arose in our mice by IHC staining using the well-established B-cell
marker, B220, and T-cell marker, CD3. As shown in Figure 3, all lymphomas stained
positive for CD3 but showed little or no staining for B220. Therefore, consistent with the
majority of previous results, the inactivation of p53 alone or in combination with SNF5
leads to the development of T-cell lymphomas.
DISCUSSION
Almost 30 years have passed since the formal recognition and diagnosis of MRT came to
exist [1,34]. While the underlying genetic defect, SNF5 loss, associated with MRT
development has been identified, this knowledge has not changed the prognosis of
individuals diagnosed with this devastating neoplasm. Given the difficulty in translating
insights gained from the molecular mechanisms of human cancer initiation and progression
to advances in clinical practice, the genetically engineered mouse model has proven
invaluable for accelerating this process. However, it has been difficult to find a suitable
GEMM for MRT because Snf5 loss results in embryonic lethality and Snf5 heterozygosity
leads to MRT development with an extended latency. Complicating matters for conditional
deletion studies, the cell of origin for MRTs remains unknown.
In the two previous studies examining the interactions between the p53 and Snf5 tumor
suppressor genes in tumor development in GEMM, loss of SNF5 function took place on a
p53 null background [23,26]. In the current mouse model, cells could lose either one or both
of these tumor suppressor pathways in order to progress to tumorigenicity. In the case of the
facial MRTs that presumably correspond to those found in Snf5+/- mice, we did not observe
an increase in penetrance or an apparent decrease in latency for the appearance of these
tumors compared to the Snf5 heterozygous mice on a p53 wild type background (Table 2).
Our data suggest that this lack of difference was associated with retention of wild-type p53
activity in these tumors. In contrast, we found an increase in penetrance and decrease in
latency for the spinal cord tumors in the Snf5+/-;p53+/- mice reminiscent of the dramatic
increase in the TgT121; Snf5+/- mice (Table 1 & 2) [22]. Therefore, it seems that cooperation
between SNF5 loss and reduced p53 expression or pRbf inactivation accelerates the
formation of these neuronally-derived tumors. Recent reports have also shown that SNF5
mutations are associated with some types of familial schwannomatosis in humans [35-37].
We also found that loss of SNF5 protein expression correlated with accelerated tumor
appearance for MRTs that occurred in locations other than the face (Table 2). This
association also held true for the time of onset of lymphomas. In contrast, we did not
observe any changes on the development of osteosarcomas in the p53+/-;Snf5+/- mice.
Several possibilities may explain the observed increase in tumor formation with the
combined haploinsufficiency of p53 and Snf5. First, Vries et al demonstrated in their 2005
study that 10% of MRT cell lines are near tetraploid and over half of the MRT cell lines bear
chromosomal aberrations [38]. They went on to show these aberrations could be corrected in
the cell population by addition of SNF5 that leads the genetically unstable cells to senesce.
Therefore, SNF5 haploinsufficient mice may experience substantial genomic instability
leading to secondary genetic events such as loss of p53 activity. This model could account
for the acceleration of development of MRTs in Snf5+/-;p53+/- mice. However, molecular
and cytogenetic studies of human MRTs suggest that genomic instability occurs
infrequently, with chromosomal aberrations localized mainly to region surrounding the
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SNF5 gene [7,13]. Furthermore, a recent report by McKenna et al. demonstrated that
genomic instability does not occur after SNF5 inactivation in genetically engineered mice
[14]. Thus, this may not provide the most likely mechanism.
A second explanation for the increase in tumor formation in the double heterozygous mice is
that p53 null cells allow genetic instability, increasing the frequency of Snf5 LOH. The role
of p53 loss in generating genetic instability in GEMM remains unresolved [39]. Some
studies have shown an increase in genetic instability after loss of p53 function while others,
including some of our own reports, suggest that its loss does not lead directly to global
chromosomal instability [39,40]. Furthermore, loss of p53 has not been found in primary
MRTs of children presenting with this disease (J. Biegel, personal communication). In fact
these tumors often initially respond well to chemotherapy and radiation and are sometimes
ablated. Unfortunately, MRTs frequently return months to years later in a chemotherapy-
resistant form in which the p53 status has not been established. Therefore, we do not favor
this paradigm to account for our findings.
We prefer a third explanation for observations in human MRT development as well as the
increase in MRTs in the double heterozygous mice. Snf5 LOH is likely occurring in the
Snf5+/-;p53+/- mice at an equivalent rate and locations as it does in the p53+/+ mice.
However, on a p53 wild type background, these Snf5 null cells are arrested or undergo
apoptosis via induction of p21 and subsequent cell cycle arrest via the RB pathway. On the
p53+/- background, most cells possess enough functional p53 to undergo these protective
processes if they lose SNF5 function. However, a few cells are able to escape them due to
low p53 levels causing a slight increase in tumor formation. Since tumors developing
following Snf5 loss have a shorter latency than those that arise following p53 loss (as
determined in previous mouse studies), an increase in Snf5+/- mouse spectrum tumors
(spinal cord and possibly limb MRTs) as well as those associated with p53 heterozygosity
(lymphomas) occurs.
Whether secondary genetic events drive the progression of malignant rhabdoid tumors
remains unresolved. Given the extensive loss of p53 in most human tumors, this study may
lead to a deeper understanding of its potential inactivation in MRT patients. The dramatic
increase in spinal cord MRTs in the Snf5+/-; p53+/- mice may implicate p53 loss in the
progression or reoccurence of atypical teratoid/rhabdoid tumors in the CNS or AT/RTs, in
human patients. While primary MRTs rarely show evidence of p53 inactivation, tumors
recurring after radiation and chemotherapeutic treatment have not been analyzed. Indeed,
several reports have demonstrated a role for p53 in survival and in the control of death
checkpoints in central nervous system neurons [41,42]. Further insight into the relationship
of classical tumor suppressor gene pathways like p53 in the etiology of MRT and its specific
interactions with SNF5 will inevitably allow for more successful treatment avenues for this
devastating childhood neoplasm.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Kaplan-Meier Survival Curve of Snf5+/-, p53+/- and Snf5+/-;p53+/- Mice
Mice were sacrificed when tumor, paralysis or physical distress was observed. Healthy mice
at 25 months were sacrificed and recorded as non-events. N values are noted on the figure.
Wild type mice experienced 100% survival at 25 months and are not included here.
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Figure 2. Representative IHC Analysis of SNF5 and p53 Expression in Primary Malignant
Rhabdoid Tumors
The tumor array was stained for p53 or SNF5 expression using the appropriate antibody and
counterstained with hematoxylin as described in the Materials and Methods. Representative
cores were visualized using a Nikon FXA microscope and captured using Q-Image software
on an Apple G4 computer. All images are 100X.
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Figure 3. Representative IHC Analysis of CD3 and B220 Expression in Primary Lymphomas
The tumor array was stained for CD3 or B220 expression using the appropriate antibody and
counterstained with Light Green or hematoxylin as described in the Materials and Methods.
Representative cores were visualized using a Nikon FXA microscope and captured using Q-
Image software on an Apple G4 computer. All images are 100X.
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Table 1
Tumor Incidence in p53+/-, Snf5+/- and Snf5+/-;p53+/- mice




Tumor Histology (# of
tumors)
Snf5 +/- 6 (n=10) 15.0 60% MRT (5 f, 1s)
p53 +/-
10 (n=15) 14.5 63%
Soft Tissue Sarcoma (4)
Lymphoma (5)
Carcinoma (1)
Snf5 +/- ;p53 +/-
32(n=43) 9.5 74%
MRT* (5f, 13s, 4other)




- one mouse had 2 MRTs, one located in the spinal cord and one located on a limb.
@
- one mouse had a lymphoma and a osteosarcoma. f-facial; s-spinal cord; other sites included limb, back, shoulder and brain.
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Table 2
Loss of Heterozygosity (LOH) Analysis of Mouse Tumors
Tissue arrays were stained for p53 and SNF5 expression as described in the Material and Methods. Each core was then scored for average signal
strength of positive tumor cells and for percentage of tumor cells demonstrating some positivity by 2 independent pathologists. These two values
were multiplied for each score and averaged for each tumor. Total scores were then assessed for significance by plotting average signal strength
versus average % positive. Bases on this analysis, we considered less than <70 as negative, 70-160 as +/- and >160 as positive.
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